An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Clinical trial NCT01578785 · TERMINATED
Trial details
- NCT number
- NCT01578785
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-03-01
- Primary completion
- 2012-10-01
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.